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Rie Ohtsuka Ohba,1 Yoko Okitsu,1 Katsura Kohata,1 Hiroto Ohguchi,1 Noriko Fukuhara,1
Hisayuki Yokoyama,1 Minami Fujiwara Yamada,1 Joji Yamamoto,1 Kenichi Ishizawa,1
Junichi Kameoka,1 Hideo Harigae11Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL) is one of the highest-risk ALL
groups. Whenever possible, patients with Ph1ALL should undergo allogeneic hematopoietic stem cell trans-
plantation (HSCT) after induction of remission. Although unrelated cord blood transplantation (CBT) has
become a common treatment in adult patients who lack a sibling donor, data on the efficacy of CBT for
Ph1ALL are limited. We analyzed the clinical outcomes of 20 Ph1ALL patients who underwent CBT
(n 5 8) or unrelated bone marrow transplantation (BMT) (n 5 12). The median age was 41 years (range,
17-55 years). All but one of the patients were treated with an imatinib-based regimen before HSCT, and
19 patients were in first complete remission (CR) and 1 patient was in second CR at the time of HSCT.
Seventeen patients received a myeloablative conditioning regimen containing 12 Gy of total-body irradiation,
and 3 received a reduced-intensity conditioning regimen. After a median of 26 months of follow-up, esti-
mated 3-year overall and leukemia-free survival rates were 100% and 85%, respectively, after CBT, and
49% and 38%, respectively, after unrelated BMT. The CBT group had significantly better overall survival
than the BMT group (P5.02). Although BCR-ABL transcript was detected in 4 of 8 CBT patients at transplan-
tation, 7 patients remained in molecular CR. Our findings suggest that CBT may be a viable option as post-
induction therapy for Ph1ALL in patients lacking a sibling donor.
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Philadelphia chromosome–positive acute lympho-
blastic leukemia (Ph1ALL) accounts for 20%-30% of
cases of adult ALL [1]. Ph1ALL is an aggressive dis-
ease with a poor prognosis, and it is not curable
when treated by standard chemotherapy alone [2-5].
The results of recent clinical trials suggest that
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chemotherapy may be a promising option to overcome
Ph1ALL [6-10]. It is well accepted that allo-HSCT
from an HLA-identical sibling donor offers the best
outcome. Approximately 70% of patients lack a suit-
able sibling donor, however. In these patients, bone
marrow (BM) fromHLA-matched unrelated volunteer
donors is usually selected as an alternative stem cell
source [11]. In patients who lack a matched unrelated
donor or require immediate transplantation due to
the aggressive nature of the disease, unrelated cord
blood (CB) may be a feasible alternative stem cell
source. Recent comparative studies have shown similar
outcomes of unrelated CB transplantation (CBT) and
unrelated BM transplantation (BMT) in adult patients
with acute leukemia [12-17]; however, there have been
a few reports detailing the efficacy and safety of CBT
in adult Ph1ALL patients. In the present study, we
compared the outcomes of unrelated CBT and
unrelated BMT in adults with Ph1ALL in complete
remission (CR).1093
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Patients
We analyzed clinical data from 20 consecutive
adult (age 16 years or older) patients with Ph1ALL
in CR undergoing unrelated CBT (n5 8) or unrelated
BMT (n 5 12) at Tohoku University Hospital and
Miyagi Cancer Center between June 2001 and April
2010. Patients lacking HLA-identical siblings were el-
igible for unrelated BMT from the Japan Marrow Do-
nor Program as the first option. Patients were typed at
the allele level at HLA-A, -B, and -DRB1, and received
6/6 or 5/6 allele-matched BM from unrelated donors.
CBT was performed only in patients lacking a fully
matched or one allele–mismatched unrelated donor
or in those in which urgent transplantation was re-
quired due to disease status. Single-unit CB serologi-
cally matching at least 4 of 6 HLA antigens and
containing .2.0  107 nucleated cells/kg of body
weight before freezing was obtained from the Japan
Cord Blood BankNetwork.Written informed consent
was obtained from all patients in accordance with the
Declaration of Helsinki.
Treatment
The transplantation protocols were approved by
the Institutional Review Boards of Tohoku University
Hospital and Miyagi Cancer Center. Pretransplanta-
tion conditioning regimens included fractionated 12
Gy of total-body irradiation (TBI) and 120 mg/kg cy-
clophosphamide (CY) (n5 12); 12 Gy TBI, 8 g/m2 cy-
tosine arabinoside, and 120 mg/kg CY (n 5 5); 125
mg/m2 fludarabine (Flu) and 160-180 mg/m2 melpha-
lan (n5 2); and 150 mg/m2 Flu, 120 mg/kg CY, and 4
Gy TBI (n5 1). Eighteen patients received tacrolimus
and methotrexate (MTX), and the other 2 patients re-
ceived cyclosporine and MTX as prophylaxis against
graft-versus-host disease (GVHD). Tacrolimus or cy-
closporine was administered i.v. starting on day -1.
MTX was given i.v. at 10 mg/m2 on day 1 and at 7
mg/m2 on days 3 and 6. All patients received granulo-
cyte colony-stimulating factor after transplantation
until granulocyte recovery was achieved. Prophylaxis
against infectious disease consisted of levofloxacin,
fluconazole, acyclovir, and trimethoprim/sulfame-
thoxazole. Cyomegalovirus (CMV) monitoring was
performed by CMV antigenemia once a week, and pa-
tients positive for CMV antigenemia were treated pre-
emptively with ganciclovir.
Definitions
The time of neutrophil recovery was defined as the
first of 3 consecutive days with an absolute neutrophil
count of at least 0.5  109/L, and platelet recovery
was defined by a platelet count of at least 20  109/L
without transfusion support for 7 continuous days.Acute GVHD (aGVHD) and chronic GVHD
(cGVHD) were graded according to established crite-
ria [18,19]. Hematologic relapse was defined as the
reappearance of any blasts in blood, .5% leukemic
cells in BM, or extramedullary leukemia. Molecular
relapse was defined as reversion to a positive
polymerase chain reaction (PCR) assay for BCR-ABL
transcripts. Treatment-related mortality (TRM) was
defined as death without evidence of hematologic
relapse.
Statistics
Patient characteristics were compared by the
Mann-Whitney U test for continuous variables. Over-
all survival (OS) was measured from the date of trans-
plantation until death or last follow-up. Leukemia-free
survival (LFS) was measured from the date of trans-
plantation until hematologic relapse, death from any
cause, or last follow-up. Survival curves for OS and
LFS were estimated by the Kaplan-Meier method
and compared by the log-rank test. All P values were
two-sided.RESULTS
Characteristics of Patients and Donors
Characteristics of the patients, their donors, and
their transplantation procedures are summarized in
Table 1. The median age was 39 years (range, 17-55
years) in CBT recipients and 42 years (range, 24-55
years) in BMT recipients. The median white blood
cell count at diagnosis was 7.7  103/mL (range,
2.4-48  103/mL) in the CBT group and 48.6  103/
mL (range, 1.4-195  103/mL) in the BMT group
(P5.11). Karyotype analysis revealed additional chro-
mosomal abnormalities in 5 of 8 patients in the CBT
group and in 5 of 12 patients in the BMT group. All
patients but onewere treatedwith imatinib in combina-
tion with standard chemotherapy before transplanta-
tion. Nineteen patients received HSCT while in first
CR (CR1), and 1 patient received HSCT while in sec-
ond CR (CR2). The median time from diagnosis to
transplantation was 204 days (range, 169-303 days) in
the CBT group and 216 days (range, 144-571 days) in
the BMT group (P5 .46).
Engraftment and GVHD
Neutrophil and platelet recovery were observed in
all 20 patients. Median time to neutrophil engraftment
was 21 days (range, 15-26 days) in patients undergoing
CBT and 16 days (range, 12-18 days) in those under-
going BMT. The overall incidences of grade II-IV
aGVHD and grade III-IV aGVHD up to day 100
posttransplantation were 50% and 0%, respectively,
in the CBT group and 25% and 16.6%, respectively,
Table 1. Characteristics of Patients and Donors
Characteristic CBT Group BMT Group
Patients, n 8 12
Age, years, median (range) 39 (17-55) 42 (24-55)
Males/females, n 3/5 6/6
Weight, kg, median (range) 57 (42-79) 60 (46-85)
White blood cell count at diagnosis,
103, median (range)
7.7 (2.4-48) 48.6 (1.4-195)
Karyotype
Philadelphia chromosome alone 3 7
Additional abnormality 5 5
Imatinib before transplantation
Yes 8 11
No 0 1
Disease status at transplantation
CR1 8 11
CR2 0 1
BCR-ABL at transplantation
Negative 4 8
Positive 4 4
Time from diagnosis to transplant,
days, median (range)
204 (169-303) 216 (144-571)
Nucleated cell dose, 107/kg, median
(range)
2.4 (1.9-2.9) 28.7 (9.9-44.6)
CD34 cell dose, 105/kg, median
(range)
0.93 (0.44-1.55) NA
HLA mismatching at antigen level
2/6 8 0
1/6 0 1
0/6 0 11
HLA mismatching at allele level
3/6 6 0
2/6 2 0
1/6 0 5
0/6 0 7
CMV serostatus (recipient/donor)
Negative/negative 1 2
Negative/positive 0 0
Positive/negative 7 5
Positive/positive 0 5
Conditioning regimen
TBI/CY 2 10
TBI/cytarabine-arabinoside/CY 5 0
Flu/melphalan 0 2
Flu/CY/low-dose TBI 1 0
GVHD prophylaxis
Tacrolimus + MTX 7 11
Cyclosporine + MTX 1 1
CBT indicates cord blood transplantation; BMT, bone marrow trans-
plantation; CR1, first complete remission; CR2, second complete
remission; NA, not available; CMV, cytomegalovirus; TBI, total body
irradiation; CY, cyclophosphamide; Flu, fludarabine; GVHD, graft-
versus-host disease; MTX, methotrexate.
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CBT group had cGVHD (4 limited, 2 extensive), com-
pared with 7 of the 10 evaluable patients in the BMT
group (3 limited, 4 extensive).Relapse, TRM, OS, and LFS
After a median follow-up of 26 months (range,
4-104 months), 8 of 8 CBT patients (100%) and 6 of
12 BMT patients (50%) were still alive. One CBT
recipient had hematologic relapse on day 370 and
was treated with dasatinib, resulting in subsequentmo-
lecular CR. Four BMT recipients had hematologic
relapse at a median of 488 days (range, 125-896
days), and all 4 of these patients died from recurrentleukemia. The study included one patient receiving
BMT in CR2, who was alive without relapse at more
than 8 years after transplantation.
Two BMT patients died from treatment-related
complications, adenovirus pneumonitis and fulminant
hepatitis, both of which occurred after corticosteroid
treatment for grade III aGVHD. These 2 patients re-
ceived BMT from a 1-antigen or 1-allele HLA- mis-
matched donor, which might affect severe aGVHD.
CMV reactivation was observed in 6 of 8 CBT patients
and in 5 of 12 BMT patients. One BMT patient had
CMV colitis, and no CBT patients had CMV disease.
The Kaplan-Meier estimates for OS and LFS at 3
years were 100% and 85%, respectively, after unre-
lated CBT and 49% and 38%, respectively, after unre-
lated BMT (Figure 1). LFS was not significantly
different between the 2 groups (P 5 .07), but the
CBT patients had significantly better OS (P 5 .02).
Minimal Residual Disease Monitoring
Molecular analysis of either minor (n5 18) or ma-
jor (n5 2) BCR-ABL transcripts were performed in all
patients before and after allo-HSCT. BCR-ABL tran-
scripts were measured by real-time quantitative PCR
(in most patients) or qualitative PCR. At the time of
transplantation, a BCR-ABL transcript was detected
in 4 of 8 patients in the CBT group and 4 of 12 patients
in the BMT group. Two of 8 PCR-positive patients
(25%) and 3 of 12 PCR-negative patients (25%) expe-
rienced hematologic recurrence of leukemia after
transplantation, demonstrating no difference in re-
lapse rate between the groups. In 4 of the 5 patients
who relapsed, molecular CR was confirmed 3 months
before hematologic relapse. Molecular relapse pre-
ceded hematologic recurrence of leukemia by amedian
of 33 days (range, 0-42 days).
In the BMT group, 2 patients experienced molec-
ular relapse and were given imatinib before overt he-
matologic relapse occurred. One of these patients
was alive inCR atmore than 4 years after themolecular
relapse; the other patient died from fulminant hepatitis
despite remaining in remission. Maintenance therapy
with imatinib was not provided after transplantation.DISCUSSION
Allo-HSCT has long been the only curative ap-
proach for adult patients with Ph1ALL [4,20-24].
Recent studies of imatinib plus intensive chemotherapy
in patients with Ph1ALL showed improved CR rates
and prolonged LFS compared with the pre-imatinib
era [6-10,25]. A combination of imatinib and
chemotherapy is considered to improve a patient’s
candidacy for HSCT [25]. Moreover, the pretransplan-
tation use of imatinib may improve outcomes of
allo-HSCT [26].
Figure 1. Kaplan–Meier estimates of OS (A) and LFS (B) in Ph1ALL pa-
tients with regard to type of donor, unrelated CBT (continuous line) and
unrelated BMT (interrupted line).
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comes of CBT in adult patients with Ph1ALL. Atsuta
et al. [16] analyzed the outcomes of allo-HSCT for
ALL in unrelated CBT and unrelated BMT recipients
(proportion of Ph1ALL cases, 38% in the CBT group
and 23% in the BMT group). They found no signifi-
cant differences in 2-year OS (CBT, 52%; BMT,
53%), LFS (CBT, 46%; BMT, 44%), and TRM
(CBT, 24%; BMT, 25%) between the CBT group
and HLA allele–matched unrelated BMT group [16].
Tomblyn et al. [17] reported similar outcomes be-
tween CBT and HSCT with related or unrelated do-
nors in patients with ALL (including 11% Ph1ALL
cases). In a study of allo-HSCT including CBT in
Ph1ALL patients, Burke et al. [26] found a 2-year
OS of 61% in 15 imatinib-treated patients, including
12 patients undergoing CBT. They posited that the fa-
vorable outcome of CBT might be due to the graft-
versus-leukemia potential provided by the greater
HLA disparity.
Consistent with these findings, we found favorable
OS (100% at 3 years) and LFS (85% at 3 years) in our
CBT recipients, although our number of patients was
small. TRM has not yet been observed in the CBT
group. Treatment with standard doses of corticoste-
roids forGVHDwas not necessary inmostCBT recip-
ients. Avoiding the use of strong immunosuppressantsmay be associated with the lowerTRMand relapse rate
in the CBT group. Together with previous reports,
these results suggest that CBmay be a promising alter-
native donor source for Ph1ALL patients lacking
a suitable HLA-matched donor.
The outcome of unrelated BMT in our series was
comparable to that reported previously [11,17,24].
However, 5 of our 12 patients received BM from
a one antigen–mismatched or one allele–mismatched
unrelated donor, which might have been associated
with a higher incidence of TRM and lower OS
compared with the CB recipients. For 7 BMT patients
who underwent transplantation from allele-matched
donors, OS and LFS at 3 years were both 64%, not sig-
nificantly different than that seen in the CBT patients.
Moreover, the BMT group had higher white blood
cell counts at diagnosis compared with the CBT group,
although the difference was not statistically significant.
This might have been associated with the higher rate of
relapse in the BMTgroup. Ten patients exhibited addi-
tional chromosomal abnormalities at diagnosis, but
their outcomes were similar to those in patients with
the Ph chromosome alone.
Bachanova et al. [27] reported an encouraging out-
come (3-year OS of 50%) in 22 patients with ALL, in-
cluding 14 with Ph1ALL, who underwent CB (n5 18)
or sibling donor (n5 4) HSCT after reduced-intensity
conditioning (RIC). In the present study, 3 patients
underwent HSCT after RIC because of their age. To
date, relapse has not occurred in the 2 surviving pa-
tients in whom BCR-ABL transcripts were not detected
at the time of transplantation. The use of imatinib dur-
ing induction chemotherapy could confer a deep mo-
lecular response, which might favorably affect the
outcome of HSCT using RIC.
Although a well-designed prospective study is
needed to define the role of CBT in patients with
Ph1ALL in CR1, our results suggest that unrelated
CBT is an encouraging option for patients with
Ph1ALL lacking a suitable HLA-matched donor.ACKNOWLEDGMENTS
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